HROW
Harrow, Inc.
Price Chart
Latest Quote
$42.87
+0.09 (+0.20%)
Current Price
| Previous Close | $42.78 |
| Open | $43.00 |
| Day High | $44.13 |
| Day Low | $42.87 |
| Volume | 96,081 |
Stock Information
| Shares Outstanding | 37.28M |
| Total Debt | $300.67M |
| Cash Equivalents | $95.97M |
| Revenue | $268.68M |
| Net Income | $-14.96M |
| Sector | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic |
| Market Cap | $1.59B |
| EPS (TTM) | $-0.38 |
| Exchange | NGM |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $1.80B |
| Sales | $268.68M |
| Income | $-14.96M |
| Book/sh | $0.77 |
| Cash/sh | $2.57 |
| Employees | 373 |
Financial Ratios
| Quick Ratio | 2.16 |
| Current Ratio | 2.48 |
| Debt/Eq | 1060.52 |
Returns & Margins
| ROA | 3.14% |
| ROE | -35.43% |
| Gross Margin | 74.11% |
| Operating Margin | -49.95% |
| Profit Margin | -5.57% |
Ownership
| Insider Ownership | 15.47% |
| Institutional Ownership | 58.86% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | 15.95 |
| P/S | 5.92 |
| P/B | 55.43 |
Analyst Data
| Recommendation | strong_buy |
| Target Price | $67.75 |
Technical Indicators
| SMA20 | $37.05 |
| SMA50 | $37.01 |
| SMA200 | $41.28 |
| RSI | 81.75 |
| ATR | 2.1870 |
| Shares Float | 28.28M |
| Short Float | 19.98% |
| Short Ratio | 6.59 |
| Volatility | 0.28 |
| Rel Volume | 0.88 |
Performance History
| Week | +11.15% |
| Month | +29.33% |
| Quarter | +21.25% |
| 6 Months | -8.02% |
| YTD | -14.49% |
| Year | +37.68% |
| 3 Years | +128.48% |
| 5 Years | +412.36% |
| 10 Years | +1053.51% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-24 | $42.68 | 704,970 |
| 2026-06-23 | $42.78 | 1,299,300 |
| 2026-06-22 | $42.41 | 831,000 |
| 2026-06-18 | $42.87 | 1,071,400 |
| 2026-06-17 | $41.94 | 1,227,000 |
| 2026-06-16 | $38.40 | 374,900 |
| 2026-06-15 | $38.93 | 608,700 |
| 2026-06-12 | $37.64 | 740,800 |
| 2026-06-11 | $37.65 | 872,700 |
| 2026-06-10 | $35.90 | 1,281,100 |
| 2026-06-09 | $33.46 | 891,300 |
| 2026-06-08 | $33.10 | 761,700 |
| 2026-06-05 | $33.19 | 649,500 |
| 2026-06-04 | $34.69 | 546,500 |
| 2026-06-03 | $33.32 | 805,800 |
| 2026-06-02 | $32.86 | 587,900 |
| 2026-06-01 | $34.11 | 525,200 |
| 2026-05-29 | $35.21 | 954,300 |
| 2026-05-28 | $35.39 | 583,800 |
| 2026-05-27 | $34.43 | 766,400 |
| 2026-05-26 | $34.17 | 992,500 |
About Harrow, Inc.
Harrow, Inc., an eyecare pharmaceutical company, engages in the discovery, development, and commercialization of ophthalmic pharmaceutical products in the United States. It operates through Branded and ImprimisRx segments. The company offers ImprimisRx, an ophthalmology-focused compounded medications. It also provides IHEEZO, a chloroprocaine hydrochloride ophthalmic gel; ophthalmic solutions, including IOPIDINE, VEVYE, and ZERVIATE, as well as BYQLOVI; MAXITROL eye drops; ILEVRO and NEVANAC, a non-steroidal and anti-inflammatory eye drop for pain and inflammation associated with cataract surgery; BYOOVIZ, a LUCENTIS biosimilar indicated for the treatment of patients with Neovascular (Wet) age-related macular degeneration (AMD), macular edema following retinal vein occlusion (RVO), and myopic choroidal neovascularization (mCNV); VIGAMOX, a fluoroquinolone antibiotic eye drop for the treatment of bacterial conjunctivitis; OPUVIZ, an EYLEA biosimilar indicated for the treatment of patients with Wet AMD, macular edema following RVO, diabetic macular edema (DME), and diabetic retinopathy (DR); MAXIDEX and FLAREX, a steroid eye drop for steroid-responsive inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe and the eye; TRIESENCE, a steroid injection for the treatment of ophthalmic diseases and for visualization during vitrectomy; and NATACYN, a sterile, antifungal drug for the treatment of fungal blepharitis, conjunctivitis, and keratitis. In addition, it offers TOBRADEX ST, a tobramycin and dexamethasone ophthalmic suspension; VERKAZIA cyclosporine ophthalmic emulsion; NEVANAC, a non-steroidal, anti-inflammatory eye drop; and FRESHKOTE preservative free (PF) is a lubricant eye drop. The company was formerly known as Harrow Health, Inc. and changed its name to Harrow, Inc. in September 2023. Harrow, Inc. was founded in 1998 and is headquartered in Nashville, Tennessee.
đ° Latest News
GROW Small Cap Equity Fund Covered Its Position in Harrow (HROW) in Q1
Insider Monkey âĸ 2026-06-23T12:06:10Z
Is Harrow, Inc. (HROW) A Good Stock To Buy Now?
Insider Monkey âĸ 2026-06-13T20:55:57Z
Can Harrowâs (HROW) VERKAZIA Relaunch Redefine Its Niche Ophthalmic Strategy?
Simply Wall St. âĸ 2026-06-12T07:12:50Z
What Does Cantor Fitzgerald Think About Harrow (HROW) After Cutting Its Price Target?
Insider Monkey âĸ 2026-06-04T21:43:53Z
Why B.Riley Reduced Harrow, Inc. (HROW) Price Target Despite Long-Term Optimism
Insider Monkey âĸ 2026-05-20T20:43:19Z
AppFolio And 2 Other High Growth Companies With Strong Insider Ownership
Simply Wall St. âĸ 2026-05-20T11:36:08Z
Mark Baum Buys Handful Of Shares In Harrow
Simply Wall St. âĸ 2026-05-17T12:44:15Z
Why Harrow (HROW) Narrative Is Shifting As Analysts Recut Targets Yet Stay Positive
Simply Wall St. âĸ 2026-05-15T13:13:50Z
The Harrow, Inc. (NASDAQ:HROW) First-Quarter Results Are Out And Analysts Have Published New Forecasts
Simply Wall St. âĸ 2026-05-14T11:21:04Z
Harrow Inc (HROW) Q1 2026 Earnings Call Highlights: Strong Product Demand Amid Revenue Challenges
GuruFocus.com âĸ 2026-05-12T19:01:35Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Reconciled Cost Of Revenue | $67,934,000 | $49,245,000 | $39,640,000 | $25,383,000 |
| Cost Of Revenue | $67,934,000 | $49,245,000 | $39,640,000 | $25,383,000 |
| Total Revenue | $272,303,000 | $199,614,000 | $130,193,000 | $88,595,000 |
| Operating Revenue | $271,909,000 | $198,619,000 | $117,447,000 | $88,595,000 |
| Expenses | ||||
| Interest Expense | $24,180,000 | $22,786,000 | $21,324,000 | $7,244,000 |
| Total Expenses | $241,788,000 | $190,539,000 | $129,382,000 | $86,676,000 |
| Other Income Expense | $-7,703,000 | $-3,609,000 | $-3,197,000 | $-8,686,000 |
| Other Non Operating Income Expenses | $47,000 | $-185,000 | $-444,000 | $102,000 |
| Net Non Operating Interest Income Expense | $-24,180,000 | $-22,786,000 | $-21,324,000 | $-7,244,000 |
| Interest Expense Non Operating | $24,180,000 | $22,786,000 | $21,324,000 | $7,244,000 |
| Operating Expense | $173,854,000 | $141,294,000 | $89,742,000 | $61,293,000 |
| Total Other Finance Cost | - | - | - | $7,244,000 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-5,139,000 | $-17,481,000 | $-24,411,000 | $-14,086,000 |
| Net Interest Income | $-24,180,000 | $-22,786,000 | $-21,324,000 | $-7,244,000 |
| Normalized Income | $983,500 | $-14,776,040 | $-22,236,130 | $-15,938,550 |
| Net Income From Continuing And Discontinued Operation | $-5,139,000 | $-17,481,000 | $-24,411,000 | $-14,086,000 |
| Total Operating Income As Reported | $30,515,000 | $8,822,000 | $431,000 | $1,919,000 |
| Net Income Common Stockholders | $-5,139,000 | $-17,481,000 | $-24,411,000 | $-14,086,000 |
| Net Income | $-5,139,000 | $-17,481,000 | $-24,411,000 | $-14,086,000 |
| Net Income Including Noncontrolling Interests | $-5,139,000 | $-17,481,000 | $-24,411,000 | $-14,086,000 |
| Net Income Continuous Operations | $-5,139,000 | $-17,481,000 | $-24,411,000 | $-14,086,000 |
| Pretax Income | $-1,368,000 | $-17,320,000 | $-23,710,000 | $-14,011,000 |
| Special Income Charges | $-7,750,000 | $-253,000 | $-5,845,000 | $5,259,000 |
| Operating Income | $30,515,000 | $9,075,000 | $811,000 | $1,919,000 |
| Gross Profit | $204,369,000 | $150,369,000 | $90,553,000 | $63,212,000 |
| Earnings From Equity Interest | - | - | $0 | $-11,133,000 |
| Per Share | ||||
| Diluted EPS | $-0.14 | $-0.49 | $-0.75 | $-0.51 |
| Basic EPS | $-0.14 | $-0.49 | $-0.75 | $-0.51 |
| Other | ||||
| Tax Effect Of Unusual Items | $-1,627,500 | $-719,040 | $-578,130 | $492,450 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $50,239,000 | $23,427,000 | $12,707,000 | $-5,447,000 |
| Total Unusual Items | $-7,750,000 | $-3,424,000 | $-2,753,000 | $2,345,000 |
| Total Unusual Items Excluding Goodwill | $-7,750,000 | $-3,424,000 | $-2,753,000 | $2,345,000 |
| Reconciled Depreciation | $19,677,000 | $14,537,000 | $12,340,000 | $3,665,000 |
| EBITDA (Bullshit earnings) | $42,489,000 | $20,003,000 | $9,954,000 | $-3,102,000 |
| EBIT | $22,812,000 | $5,466,000 | $-2,386,000 | $-6,767,000 |
| Diluted Average Shares | $36,707,143 | $35,650,714 | $32,616,777 | $27,619,608 |
| Basic Average Shares | $36,707,143 | $35,650,714 | $32,616,777 | $27,619,608 |
| Diluted NI Availto Com Stockholders | $-5,139,000 | $-17,481,000 | $-24,411,000 | $-14,086,000 |
| Tax Provision | $3,771,000 | $161,000 | $701,000 | $75,000 |
| Other Special Charges | $7,750,000 | - | $5,465,000 | - |
| Impairment Of Capital Assets | $0 | $253,000 | $380,000 | $0 |
| Research And Development | $20,940,000 | $12,230,000 | $6,652,000 | $3,050,000 |
| Selling General And Administration | $152,914,000 | $129,064,000 | $83,090,000 | $58,243,000 |
| Gain On Sale Of Security | - | $-3,171,000 | $3,092,000 | $-2,914,000 |
| Gain On Sale Of Ppe | - | - | $0 | $5,259,000 |
| Preferred Stock Dividends | - | - | - | - |
| Minority Interests | - | - | - | - |
Fetched: 2026-06-24
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $-124,243,000 | $-117,380,000 | $-91,610,000 | $1,426,000 |
| Total Assets | $399,482,000 | $388,971,000 | $312,164,000 | $157,378,000 |
| Total Non Current Assets | $187,732,000 | $199,320,000 | $172,682,000 | $39,118,000 |
| Goodwill And Other Intangible Assets | $176,689,000 | $187,032,000 | $162,376,000 | $26,169,000 |
| Other Intangible Assets | $176,357,000 | $186,700,000 | $162,044,000 | $25,837,000 |
| Current Assets | $211,750,000 | $189,651,000 | $139,482,000 | $118,260,000 |
| Other Current Assets | $2,128,000 | $3,410,000 | $1,753,000 | $118,000 |
| Prepaid Assets | $12,277,000 | $11,691,000 | $7,198,000 | $3,354,000 |
| Inventory | $13,523,000 | $10,702,000 | $10,867,000 | $6,541,000 |
| Receivables | $110,895,000 | $116,601,000 | $36,489,000 | $6,388,000 |
| Accounts Receivable | $110,895,000 | $116,373,000 | $36,261,000 | $6,249,000 |
| Allowance For Doubtful Accounts Receivable | $-27,029,000 | $-20,147,000 | $-15,246,000 | $-779,000 |
| Gross Accounts Receivable | $137,924,000 | $136,520,000 | $51,507,000 | $7,028,000 |
| Cash Cash Equivalents And Short Term Investments | $72,927,000 | $47,247,000 | $82,766,000 | $101,859,000 |
| Cash And Cash Equivalents | $72,927,000 | $47,247,000 | $74,085,000 | $96,270,000 |
| Cash Financial | $72,927,000 | $47,247,000 | $74,085,000 | $96,270,000 |
| Current Deferred Assets | - | $0 | $409,000 | $0 |
| Non Current Deferred Assets | - | - | $0 | $1,950,000 |
| Debt | ||||
| Net Debt | $170,257,000 | $172,292,000 | $111,800,000 | $7,904,000 |
| Total Debt | $251,976,000 | $228,828,000 | $193,215,000 | $112,229,000 |
| Long Term Debt And Capital Lease Obligation | $251,089,000 | $228,331,000 | $192,409,000 | $111,506,000 |
| Long Term Debt | $243,184,000 | $219,539,000 | $185,885,000 | $104,174,000 |
| Current Debt And Capital Lease Obligation | $887,000 | $497,000 | $806,000 | $723,000 |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $347,391,000 | $319,674,000 | $241,753,000 | $130,138,000 |
| Total Non Current Liabilities Net Minority Interest | $251,089,000 | $228,331,000 | $192,409,000 | $111,506,000 |
| Current Liabilities | $96,302,000 | $91,343,000 | $49,344,000 | $18,632,000 |
| Current Deferred Liabilities | $788,000 | $44,000 | $75,000 | $113,000 |
| Payables And Accrued Expenses | $94,627,000 | $90,802,000 | $48,463,000 | $17,796,000 |
| Interest Payable | $6,498,000 | $2,538,000 | $1,978,000 | $1,254,000 |
| Payables | $35,355,000 | $38,762,000 | $21,424,000 | $6,440,000 |
| Accounts Payable | $35,355,000 | $38,762,000 | $21,424,000 | $6,440,000 |
| Equity | ||||
| Common Stock Equity | $52,446,000 | $69,652,000 | $70,766,000 | $27,595,000 |
| Total Equity Gross Minority Interest | $52,091,000 | $69,297,000 | $70,411,000 | $27,240,000 |
| Stockholders Equity | $52,446,000 | $69,652,000 | $70,766,000 | $27,595,000 |
| Retained Earnings | $-156,524,000 | $-151,385,000 | $-133,904,000 | $-109,493,000 |
| Long Term Equity Investment | - | - | - | $0 |
| Other | ||||
| Ordinary Shares Number | $37,229,159 | $35,622,214 | $35,168,260 | $29,901,530 |
| Share Issued | $37,229,159 | $35,622,214 | $35,168,260 | $29,901,530 |
| Tangible Book Value | $-124,243,000 | $-117,380,000 | $-91,610,000 | $1,426,000 |
| Invested Capital | $295,630,000 | $289,191,000 | $256,651,000 | $131,769,000 |
| Working Capital | $115,448,000 | $98,308,000 | $90,138,000 | $99,628,000 |
| Capital Lease Obligations | $8,792,000 | $9,289,000 | $7,330,000 | $8,055,000 |
| Total Capitalization | $295,630,000 | $289,191,000 | $256,651,000 | $131,769,000 |
| Minority Interest | $-355,000 | $-355,000 | $-355,000 | $-355,000 |
| Additional Paid In Capital | $208,933,000 | $221,002,000 | $204,635,000 | $137,058,000 |
| Capital Stock | $37,000 | $35,000 | $35,000 | $30,000 |
| Common Stock | $37,000 | $35,000 | $35,000 | $30,000 |
| Long Term Capital Lease Obligation | $7,905,000 | $8,792,000 | $6,524,000 | $7,332,000 |
| Current Deferred Revenue | $788,000 | $44,000 | $75,000 | $113,000 |
| Current Capital Lease Obligation | $887,000 | $497,000 | $806,000 | $723,000 |
| Current Accrued Expenses | $59,272,000 | $52,040,000 | $27,039,000 | $11,356,000 |
| Goodwill | $332,000 | $332,000 | $332,000 | $332,000 |
| Net PPE | $11,043,000 | $12,288,000 | $10,306,000 | $10,999,000 |
| Accumulated Depreciation | $-12,224,000 | $-11,014,000 | $-10,072,000 | $-9,061,000 |
| Gross PPE | $23,267,000 | $23,302,000 | $20,378,000 | $20,060,000 |
| Leases | $7,430,000 | $7,291,000 | $6,771,000 | $6,449,000 |
| Other Properties | $13,707,000 | $13,860,000 | $11,349,000 | $11,772,000 |
| Machinery Furniture Equipment | $2,130,000 | $2,151,000 | $2,258,000 | $1,839,000 |
| Properties | $0 | $0 | $0 | $0 |
| Finished Goods | $5,529,000 | $4,482,000 | $5,336,000 | $2,796,000 |
| Work In Process | $1,036,000 | $858,000 | $54,000 | $38,000 |
| Raw Materials | $6,958,000 | $5,362,000 | $5,477,000 | $3,707,000 |
| Duefrom Related Parties Current | $0 | $228,000 | $228,000 | $139,000 |
| Other Short Term Investments | - | $0 | $8,681,000 | $5,589,000 |
| Non Current Accrued Expenses | - | - | $2,713,000 | $0 |
| Buildings And Improvements | - | - | $6,785,000 | $7,513,000 |
| Investments And Advances | - | - | - | $0 |
| Investmentsin Subsidiariesat Cost | - | - | - | $0 |
Fetched: 2026-06-24
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $42,762,000 | $-60,876,000 | $-148,713,000 | $-6,068,000 |
| Operating Activities | ||||
| Operating Cash Flow | $43,864,000 | $-22,202,000 | $3,840,000 | $1,705,000 |
| Cash Flow From Continuing Operating Activities | $43,864,000 | $-22,202,000 | $3,840,000 | $1,705,000 |
| Operating Gains Losses | $12,121,000 | $3,171,000 | $2,541,000 | $8,857,000 |
| Investing Activities | ||||
| Capital Expenditure | $-1,102,000 | $-38,674,000 | $-152,553,000 | $-7,773,000 |
| Investing Cash Flow | $-5,460,000 | $-33,164,000 | $-152,553,000 | $-1,743,000 |
| Cash Flow From Continuing Investing Activities | $-5,460,000 | $-33,164,000 | $-152,553,000 | $-1,743,000 |
| Net Other Investing Changes | - | - | - | $6,000,000 |
| Capital Expenditure Reported | - | - | - | $0 |
| Financing Activities | ||||
| Issuance Of Capital Stock | $0 | $0 | $138,072,000 | $22,655,000 |
| Financing Cash Flow | $-12,724,000 | $28,528,000 | $126,528,000 | $54,141,000 |
| Cash Flow From Continuing Financing Activities | $-12,724,000 | $28,528,000 | $126,528,000 | $54,141,000 |
| Net Other Financing Charges | $-26,663,000 | $-2,362,000 | $-13,013,000 | $-876,000 |
| Net Common Stock Issuance | $0 | $0 | $138,072,000 | $22,655,000 |
| Common Stock Issuance | $0 | $0 | $138,072,000 | $22,655,000 |
| Repurchase Of Capital Stock | - | - | - | $0 |
| Cash Dividends Paid | - | - | - | $0 |
| Preferred Stock Dividend Paid | - | - | - | $0 |
| Net Preferred Stock Issuance | - | - | - | $0 |
| Preferred Stock Issuance | - | - | - | $0 |
| Other | ||||
| Repayment Of Debt | $-230,903,000 | $0 | $-59,750,000 | $-18,000 |
| Issuance Of Debt | $244,375,000 | $29,780,000 | $60,840,000 | $31,738,000 |
| Interest Paid Supplemental Data | $18,718,000 | $20,594,000 | $18,887,000 | $6,480,000 |
| Income Tax Paid Supplemental Data | $93,000 | $374,000 | $0 | $75,000 |
| End Cash Position | $72,927,000 | $47,247,000 | $74,085,000 | $96,270,000 |
| Beginning Cash Position | $47,247,000 | $74,085,000 | $96,270,000 | $42,167,000 |
| Changes In Cash | $25,680,000 | $-26,838,000 | $-22,185,000 | $54,103,000 |
| Proceeds From Stock Option Exercised | $467,000 | $1,110,000 | $379,000 | $642,000 |
| Net Issuance Payments Of Debt | $13,472,000 | $29,780,000 | $1,090,000 | $31,720,000 |
| Net Long Term Debt Issuance | $13,472,000 | $29,780,000 | $1,090,000 | $31,720,000 |
| Long Term Debt Payments | $-230,903,000 | $0 | $-59,750,000 | $-18,000 |
| Long Term Debt Issuance | $244,375,000 | $29,780,000 | $60,840,000 | $31,738,000 |
| Net Investment Purchase And Sale | $0 | $5,510,000 | $0 | $0 |
| Sale Of Investment | $0 | $5,510,000 | $0 | $0 |
| Net Business Purchase And Sale | $-4,358,000 | $0 | $0 | - |
| Purchase Of Business | $-4,358,000 | $0 | $0 | - |
| Net Intangibles Purchase And Sale | $-215,000 | $-37,079,000 | $-151,093,000 | $-5,176,000 |
| Purchase Of Intangibles | $-215,000 | $-37,079,000 | $-151,093,000 | $-5,176,000 |
| Net PPE Purchase And Sale | $-887,000 | $-1,595,000 | $-1,460,000 | $-2,567,000 |
| Purchase Of PPE | $-887,000 | $-1,595,000 | $-1,460,000 | $-2,597,000 |
| Change In Working Capital | $185,000 | $-44,626,000 | $-7,135,000 | $-5,568,000 |
| Change In Other Working Capital | $744,000 | $-31,000 | $-38,000 | $97,000 |
| Change In Payables And Accrued Expense | $-3,672,000 | $41,544,000 | $33,220,000 | $1,869,000 |
| Change In Accrued Expense | $936,000 | $4,046,000 | $1,425,000 | $936,000 |
| Change In Payable | $-4,608,000 | $37,498,000 | $31,795,000 | $933,000 |
| Change In Account Payable | $-4,608,000 | $37,498,000 | $31,795,000 | $933,000 |
| Change In Prepaid Assets | $924,000 | $-6,072,000 | $-5,647,000 | $-3,350,000 |
| Change In Inventory | $-2,821,000 | $165,000 | $-4,326,000 | $-2,324,000 |
| Change In Receivables | $5,010,000 | $-80,232,000 | $-30,344,000 | $-1,860,000 |
| Changes In Account Receivables | $5,010,000 | $-80,232,000 | $-30,344,000 | $-1,860,000 |
| Other Non Cash Items | $4,050,000 | $4,205,000 | $4,097,000 | $782,000 |
| Stock Based Compensation | $12,502,000 | $17,619,000 | $15,696,000 | $7,974,000 |
| Provisionand Write Offof Assets | $468,000 | $120,000 | $332,000 | $81,000 |
| Asset Impairment Charge | $0 | $253,000 | $380,000 | $0 |
| Depreciation Amortization Depletion | $19,677,000 | $14,537,000 | $12,340,000 | $3,665,000 |
| Depreciation And Amortization | $19,677,000 | $14,537,000 | $12,340,000 | $3,665,000 |
| Amortization Cash Flow | $17,591,000 | $12,364,000 | $10,557,000 | $1,578,000 |
| Amortization Of Intangibles | $17,591,000 | $12,364,000 | $10,557,000 | $1,578,000 |
| Depreciation | $2,086,000 | $2,173,000 | $1,783,000 | $2,087,000 |
| Earnings Losses From Equity Investments | $0 | $3,171,000 | $-3,092,000 | $14,047,000 |
| Gain Loss On Sale Of PPE | $13,000 | $0 | $168,000 | $-5,190,000 |
| Gain Loss On Sale Of Business | $4,358,000 | $0 | $0 | - |
| Net Income From Continuing Operations | $-5,139,000 | $-17,481,000 | $-24,411,000 | $-14,086,000 |
| Sale Of PPE | - | - | $0 | $30,000 |
| Preferred Stock Payments | - | - | - | $0 |
| Sale Of Business | - | - | - | - |
Fetched: 2026-06-24